ମାଇପୋମର୍ସନ

ଉଇକିପିଡ଼ିଆ‌ରୁ


ମାଇପୋମର୍ସନ
Clinical data
Trade namesKynamro
SynonymsISIS 301012
AHFS/Drugs.commonograph
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
Subcutaneous injection
Legal status
Legal status
Pharmacokinetic data
Protein binding≥90%
MetabolismNucleases
Elimination half-life1–2 months
Excretion<4% in urine in 24 hours
Identifiers
  • 2’-O-(2-Methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-deoxy-P-thioadenylyl-(3’→5’)-2’-deoxy-P-thioguanylyl-(3’→5’)-P- thiothymidylyl-(3’→5’)-2’-deoxy-5-methyl-P-thiocytidylyl-(3’→5’)-P-thiothymidylyl-(3’→5’)-2’-deoxy-P-thioguanylyl-(3’→5’)-2’-deoxy-5-methyl-P-thiocytidylyl-(3’→5’)-P-thiothymidylyl-(3’→5’)-P-thiothymidylyl-(3’→5’)-2’-deoxy-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl- (3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methylcytidine nonadecasodiumsalt
Chemical and physical data
FormulaC230H305N67Na19O122P19S19
Molar mass୭,୫୯୪.୭୬ g·mol−1
3D model (JSmol)
  • COCCO[C@@H]1[C@H](OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H](C[C@@H]2OP(=S)(OC[C@H]2O[C@H]([C@@H]([C@@H]2OP(=S)(OC[C@H]2O[C@H]([C@@H]([C@@H]2OP(=S)(OC[C@H]2O[C@H]([C@@H]([C@@H]2OP(=S)(OC[C@H]2O[C@H]([C@@H]([C@@H]2OP(=S)(OC[C@H]2O[C@H]([C@@H]([C@@H]2O)OCCOC)n2cc(C)c(nc2=O)N)O)OCCOC)n2cc(C)c(nc2=O)N)O)OCCOC)n2cnc3c2ncnc3N)O)OCCOC)n2cc(C)c(nc2=O)N)O)OCCOC)n2cnc3c2nc(N)[nH]c3=O)O)n2cc(C)c(nc2=O)N)O)n2cc(C)c(=O)[nH]c2=O)O)n2cc(C)c(=O)[nH]c2=O)O)n2cc(C)c(nc2=O)N)O)n2cnc3c2nc(N)[nH]c3=O)O)n2cc(C)c(=O)[nH]c2=O)O)n2cc(C)c(nc2=O)N)O)n2cc(C)c(=O)[nH]c2=O)O)n2cnc3c2nc(N)[nH]c3=O)O)n2cnc3c2ncnc3N)O)[C@H](O[C@H]1n1cc(C)c(nc1=O)N)COP(=S)(O[C@@H]1[C@@H](COP(=S)(O[C@@H]2[C@@H](COP(=S)(O[C@@H]3[C@@H](COP(=S)(O[C@@H]4[C@@H](CO)O[C@H]([C@@H]4OCCOC)n4cnc5c4nc(N)[nH]c5=O)O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(nc3=O)N)O)O[C@H]([C@@H]2OCCOC)n2cc(C)c(nc2=O)N)O)O[C@H]([C@@H]1OCCOC)n1cc(C)c(=O)[nH]c1=O)O
  • InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-111(122(381-141)70-362-422(325,441)404-116-50-146(283-66-108(12)196(302)275-228(283)320)387-128(116)76-368-427(330,446)410-120-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)390-130(120)78-370-428(331,447)408-118-52-148(292-91-250-151-186(240)246-89-248-188(151)292)388-131(118)79-371-430(333,449)412-159-134(394-204(169(159)354-37-27-344-17)286-59-101(5)181(235)260-221(286)313)83-375-435(338,454)417-164-138(398-209(174(164)359-42-32-349-22)291-68-110(14)198(304)277-230(291)322)87-377-434(337,453)415-162-136(396-207(172(162)357-40-30-347-20)289-62-104(8)184(238)263-224(289)316)85-376-433(336,452)414-161-133(393-206(171(161)356-39-29-346-19)288-61-103(7)183(237)262-223(288)315)82-374-432(335,451)411-158-121(69-298)391-211(168(158)353-36-26-343-16)296-95-254-155-192(296)267-215(244)271-201(155)307)401-420(323,439)365-74-127-117(51-147(386-127)284-67-109(13)197(303)276-229(284)321)406-425(328,444)369-77-129-119(53-149(389-129)293-92-252-153-190(293)265-213(242)269-199(153)305)409-426(329,445)367-71-123-112(46-142(382-123)279-56-98(2)178(232)257-218(279)310)402-421(324,440)364-73-125-115(49-145(384-125)282-65-107(11)195(301)274-227(282)319)405-424(327,443)366-75-126-114(48-144(385-126)281-64-106(10)194(300)273-226(281)318)403-423(326,442)363-72-124-113(47-143(383-124)280-57-99(3)179(233)258-219(280)311)407-429(332,448)373-81-139-166(176(361-44-34-351-24)212(400-139)297-96-255-156-193(297)268-216(245)272-202(156)308)419-438(341,457)379-86-137-163(173(358-41-31-348-21)208(397-137)290-63-105(9)185(239)264-225(290)317)416-436(339,455)380-88-140-165(175(360-43-33-350-23)210(399-140)295-94-251-152-187(241)247-90-249-189(152)295)418-437(340,456)378-84-135-160(170(355-38-28-345-18)205(395-135)287-60-102(6)182(236)261-222(287)314)413-431(334,450)372-80-132-157(299)167(352-35-25-342-15)203(392-132)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,203+,204+,205+,206+,207+,208+,209+,210+,211+,212+,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m0/s1
  • Key:XLTMQWVJFPYGMC-QVKFEXRMSA-N

ମାଇପୋମର୍ସନ (ଇଂରାଜୀ ଭାଷାରେ Mipomersen), କିନାମ୍ରୋ ଏହାର ଏକ ବେପାର ନାମ, ହେଉଛ ଏକ ଔଷଧ ଯାହା ହୋମୋଜାଇଗସ୍ ପାରିବାରିକ ହାଇପରକୋଲେଷ୍ଟେରୋମିଆର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।[୧] ହୃଦଘାତ କିମ୍ବା ମୃତ୍ୟୁର ସାମଗ୍ରିକ ବିପଦ ଉପରେ ଏହାର ପ୍ରଭାବ ଅସ୍ପଷ୍ଟ ଅଛି ।[୧] ଅନ୍ୟ କେତେକ ପ୍ରକାରର ଉଚ୍ଚ କୋଲେଷ୍ଟେରଲର ଉପକାର ଅଜ୍ଞାତ ଅଟେ ।[୧] ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଏହା ଦିଆଯାଏ ।[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କାଣ, ଅଇ, ମୁଣ୍ଡବିନ୍ଧା, ଯକୃତ ସମସ୍ୟା, ଜ୍ୱର, ଉଚ୍ଚ ରକ୍ତଚାପ ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।[୧] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଞ୍ଜିଓଇଡିମା ଓ ଇଞ୍ଜେକ୍ସନ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।[୧] ଏହା ଡିଏନ୍ଏର ଏକ କ୍ଷୁଦ୍ର ଖଣ୍ଡ, ଯାହା ଆଣ୍ଟିସେନ୍ସ ଓଲିଗୋନ୍ୟୁକ୍ଲିଓଟାଇଡ ଭାବରେ ଜଣାଶୁଣା, ଯାହା ଆପୋଲିପୋପ୍ରୋଟେନ୍-ବି ଉତ୍ପାଦନକୁ ଅବରୋଧ କରିଥାଏ ।[୨]

୨୦୧୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ମାଇପୋମର୍ସନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।[୧] ୟୁରୋପରେ ଏହାର ଉପକାର ଅପେକ୍ଷା ଅଧିକ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ଚିନ୍ତା ହେତୁ ୨୦୧୩ରେ ଏହାକୁ ଅନୁମୋଦନ ପ୍ରତ୍ୟାଖ୍ୟାନ କରାଯାଇଥିଲା ।[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ଏକ ବର୍ଷର ମୂଲ୍ୟ ପ୍ରାୟ ୪୦୭,୦୦୦ ଡଲାର ।[୩]

ଆଧାର

  1. ୧.୦ ୧.୧ ୧.୨ ୧.୩ ୧.୪ ୧.୫ ୧.୬ "Mipomersen Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 24 January 2021. Retrieved 18 November 2021.
  2. ୨.୦ ୨.୧ "Kynamro". Archived from the original on 8 March 2021. Retrieved 18 November 2021.
  3. "Kynamro Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 18 November 2021.